Ivy Natal: Funding, Investors & Team (Sep 2026)
Many women cannot have children except through the use of donor eggs. This can be due to surgery, chemotherapy, age, or genetic conditions. We aim to allow these patients to have genetic children for the first time, using a process which starts with a simple skin biopsy. Our approach directly activates the skin cell’s existing DNA to transform it into a new, healthy egg cell. This avoids the challenges with traditional approaches to producing eggs and sperm in vitro. Our goal is to give women confidence in their ability to choose whether and when to have a child—and in the long term, ensure that every person and couple has the choice to have genetic children, including same-sex couples.
Ivy Natal has raised $1.5M across 1 funding round on record, the most recent an undisclosed round of $1.5M announced in Dec 2022.
That round is below the $8.0M median round size for Biotechnology companies tracked on FundedIQ over the last two years.
Ivy Natal Company Profile and Key Stats
Latest funding round on record: Dec 2022.
Ivy Natal Funding Rounds
Ivy Natal Founders and Leadership Team
Contact details for the Ivy Natal team: 1 of 1 has an email address on file.
Start 14-day free trial →Ivy Natal Funding Compared to Other Biotechnology Startups
Ivy Natal's latest round of $1.5M is below the median round in Biotechnology. Medians cover the last 24 months of disclosed rounds.
Funded Startups Like Ivy Natal in Biotechnology and San Francisco
Companies Similar to Ivy Natal
Noveome Biotherapeutics, Inc. is an advanced biopharmaceutical company that focuses on groundbreaking…
XiltriX North America is an information technology company that specializes in monitoring, predictive…
Novir is an emerging diagnostic biotechnology company with an unmatched team of professionals and trusted…
Abcuro’s mission is to develop a new class of immune-modulatory bio-therapeutics for treating both…
Georgiamune Inc. is a privately-owned biotechnology company that specializes in advanced immunotherapy…
Bridge to Life was founded with the mission of improving organ transplants by licensing and developing new…
InduPro is a biotechnology firm that focuses on protein therapeutics and technologies related to cell-surface…
Paterna BioSciences, Inc. is a pioneering biotechnology company dedicated to solving the significant…
Legendary Bio's solidarity is a determined spotlight on introducing another period of quality guideline.
Cataract surgery is the single most common procedure performed in the United States annually. Despite…
InSitu Biologics is a developer of a drug delivery platform designed to focus on development of new and…
Remedium Bio is a gene therapy company in the Boston area that is dedicated to developing cures for severe…
Ivy Natal Funding FAQs
What does Ivy Natal do?
Many women cannot have children except through the use of donor eggs. This can be due to surgery, chemotherapy, age, or genetic conditions. We aim to allow these patients to have genetic children for the first time, using a process which starts with a simple skin biopsy. Our approach directly activates the skin cell’s existing DNA to transform it into a new, healthy egg cell. This avoids the challenges with traditional approaches to producing eggs and sperm in vitro. Our goal is to give women confidence in their ability to choose whether and when to have a child—and in the long term, ensure that every person and couple has the choice to have genetic children, including same-sex couples.
How much funding has Ivy Natal raised?
Ivy Natal has raised $1.5M across 1 round on record. The most recent is an undisclosed round of $1.5M announced in Dec 2022.
When did Ivy Natal last raise funding?
Ivy Natal's most recent funding round on record is an undisclosed round of $1.5M, announced in Dec 2022.
Who founded Ivy Natal?
FundedIQ lists Jeffrey Hsu (Founder) at Ivy Natal.
Where is Ivy Natal headquartered?
Ivy Natal is based in San Francisco, California, United States.
How many employees does Ivy Natal have?
Ivy Natal is in the 1-10 employee band.
How does Ivy Natal's funding compare to other Biotechnology startups?
Ivy Natal's latest round of $1.5M is below the $8.0M median round size for Biotechnology companies on FundedIQ across 4,179 tracked companies over the last two years.
About FundedIQ's Ivy Natal Funding Data
FundedIQ tracks announced funding rounds and refreshes this profile every week. Round dates, stages and amounts are normalised to a single format, converted to US dollars, and de-duplicated: two records of the same round announced days apart are merged, and two genuinely different rounds are kept apart on the amounts they disclose. Amounts shown are the disclosed figures only — a round announced without a number is listed and excluded from the total rather than estimated.
Employee counts are reported bands, not exact headcounts. Founder and executive names carry the job title on record. Anything we do not hold for Ivy Natal is left off this page rather than filled in.
Know who just raised. Then know who to reach.
Every newly funded startup with its round, its investors and its founders: delivered weekly by email, or searchable in the app.
Alerts from $19/mo · Pro from $99/mo. Card required, nothing charged until day 15, and we email you 3 days before that.